Mithra takes note of François Fornieri’s indictment

Liege, Belgium, 28 avril 2021 – 21:15 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces having been informed of François Fornieri’s indictment of alleged insider dealing charges following his audition held in Liège today by the federal judicial police.

Mithra reminds that since February 04, 2021, Mr. Fornieri no longer performs any management functions within the company and that the CEO function is now assumed by Mr Leon Van Rompay. Therefore, the indictment of Mr. Fornieri does not have any impact on the operational management of the company’s activities. Following the recent approvals obtained for its contraceptive product Estelle®, Mithra is more than ever focused on its ambitious objectives.

Mithra Releases 2020 Annual Report and Invitation to its Securities holders’ Meeting

Liege, Belgium, 20 April 2021 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the publication of its 2020 Annual Report and the invitation to its ordinary and extraordinary general meeting of securities holders.

2020 Annual Report

The Annual Report which outlines Mithra’s achievements in 2020 includes the following information:

  • Overview of Mithra’s R&D pipeline and Letter to Shareholders;
  • Highlights of Mithra’s Strategy and Outlook for 2021;
  • Management Report;
  • Remuneration Report;
  • Financial statements and notes.

The Annual Report is available in English and French and can be read (or downloaded in PDF) on the website report2020.mithra.com or on investors.mithra.com. In case of interpretation differences, the French version will prevail.


General Shareholders’ meeting

Mithra is pleased to invite its securities holders to its ordinary and extraordinary general shareholder’s meeting that will be held on Thursday May 20 2021 at 2:00 PM (CEST).

The notice for the General Shareholder’s Meeting including a description of the formalities to participate in the Meeting is available on the website investors.mithra.com.

Mayne Pharma and Mithra Announce FDA Approval of New Oral Contraceptive Estelle®

15 April 2021, 22:30 CEST, Adelaide, Australia and Liege, Belgium: Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for the novel combined oral contraceptive Estelle® under the trademark Nextstellis® (15 mg Estetrol (E4) / 3 mg drospirenone (DRSP)). Mayne Pharma anticipates the commercial launch of Estelle® by the end of June 2021.